Literature DB >> 12363434

A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery.

J Frank T Griffin1.   

Abstract

One of the most pressing issues in animal and human medicine currently is the need to develop new and more effective vaccines, against an ever increasing range of infectious diseases. Traditional vaccines have involved the use of killed microorganisms, live attenuated cultures or antigenic extracts. In spite of extensive research, there have been very few newly developed vaccines for humans or animals, over the past 20 years. Recent developments in our understanding of the pathways of immunity required to produce protection against different infections, allow immunological principles to be incorporated into the design new and better vaccines. This paper outlines the key variables that need to be taken into consideration when developing a new vaccine. Three critical areas will be considered in the review: (1) use of an appropriate experimental animal model of infection; (2) targeting appropriate immune markers for protection; (3) design of optimal vaccine formulation and delivery systems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363434     DOI: 10.1016/s0169-409x(02)00072-8

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  15 in total

Review 1.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 2.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

Review 3.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

Review 4.  Onchocerca volvulus: The Road from Basic Biology to a Vaccine.

Authors:  Sara Lustigman; Benjamin L Makepeace; Thomas R Klei; Simon A Babayan; Peter Hotez; David Abraham; Maria Elena Bottazzi
Journal:  Trends Parasitol       Date:  2017-09-22

5.  Modeling binge-like ethanol drinking by peri-adolescent and adult P rats.

Authors:  Richard L Bell; Zachary A Rodd; Rebecca J Smith; Jamie E Toalston; Kelle M Franklin; William J McBride
Journal:  Pharmacol Biochem Behav       Date:  2011-07-29       Impact factor: 3.533

6.  Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats.

Authors:  Richard L Bell; Bill J A Eiler; Jason B Cook; Shafiqur Rahman
Journal:  Alcohol       Date:  2009-12       Impact factor: 2.405

Review 7.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

Review 8.  Scheduled access alcohol drinking by alcohol-preferring (P) and high-alcohol-drinking (HAD) rats: modeling adolescent and adult binge-like drinking.

Authors:  Richard L Bell; Zachary A Rodd; Eric A Engleman; Jamie E Toalston; William J McBride
Journal:  Alcohol       Date:  2013-10-31       Impact factor: 2.405

Review 9.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

Review 10.  The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.

Authors:  E A Engleman; Z A Rodd; R L Bell; J M Murphy
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.